Voranigo (vorasidenib) for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation
August 6, 2024
Stay current on the FDA's new approvals and expanded indications in the oncology field. For select new agents, you'll also find video commentary from a clinical pharmacist expert, sharing their perspective on how the news affects the treatment landscape and what the advanced practitioner needs to know.
August 6, 2024
December 4, 2024
December 4, 2024
November 20, 2024
November 15, 2024
November 8, 2024
October 29, 2024
October 18, 2024
October 10, 2024
October 3, 2024
September 27, 2024
September 25, 2024
September 20, 2024
September 19, 2024
September 17, 2024
September 17, 2024
September 12, 2024
August 19, 2024
August 15, 2024
August 14, 2024
August 2, 2024
August 1, 2024
Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPO
November 26, 2024
Erin Hickey Zacholski, PharmD, BCOP, Sarah Rugh, PharmD Candidate, Jenna Marshall, PharmD Candidate, Et al.
November 26, 2024
Lindsay Knox, FNP-C
November 26, 2024